<DOC>
	<DOC>NCT00733642</DOC>
	<brief_summary>The purpose of this study is to determine whether single doses of PF-04360365 is safe and well tolerated in patients with Alzheimer's Disease.</brief_summary>
	<brief_title>Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male or female (of nonchild bearing potential) subjects ages ≥50 years of age. Diagnosis of probable AD (of mild to moderate severity), consistent with criteria from both: NINCDSAlzheimer's Disease and Related Disorders Association (ADRDA) and DSMIVTR. MMSE score of 1626 inclusive. RosenModified Hachinski Ischemia Score ≤4. On a stable dose of background cholinesterase inhibitors or memantine for at least 60 days prior to dosing. Diagnosis or history of other dementia or neurodegenerative disorders. Diagnosis or history of clinically significant cerebrovascular disease. Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes. History of allergic or anaphylactic reactions.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>antibody amyloid Alzheimer's Disease AD</keyword>
</DOC>